Thomas Bures
Patrimonio netto: 188 330 $ in data 31/05/2026
Patrimonio netto: 188 330 $ in data 31/05/2026
Thomas Bures is Chief Accounting Officer at Bruker Corp.
since 2025.
Formerly, Mr. Bures was Senior VP, Chief Financial & Accounting Officer at Pieris Pharmaceuticals, Inc. from 2021 to 2024, Vice President & Controller at Genocea Biosciences, Inc. from 2015 to 2017, Vice President & Assistant Controller at PAREXEL International Corp., and Chief Financial Officer at Palvella Therapeutics, Inc. Education includes an undergraduate degree from College of the Holy Cross (Massachusetts).
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/02/2026 | 3.198 ( 0% ) | 188 330 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BRUKER CORPORATION | Comptroller/Controller/Auditor | 13/01/2025 |
| Società | Posizione | Fine |
|---|---|---|
| PIERIS PHARMACEUTICALS | Direttore Finanziario/CFO | 13/12/2024 |
| GENOCEA BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 01/12/2017 |
| PAREXEL INTERNATIONAL CORPORATION | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
PAREXEL International Corp.
PAREXEL International Corp. BiotechnologyHealth Technology Operates as a clinical research organization which provides insights-driven clinical and consulting solutions | Health Technology |
Bruker Corp.
Bruker Corp. Medical SpecialtiesHealth Technology Manufactures analytical and medical instruments | Health Technology |
Genocea Biosciences, Inc.
Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
College of the Holy Cross (Massachusetts)
College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale